AtaiBeckley Appoints Michael Faerm as Chief Financial Officer
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026.
Mr. Faerm is a seasoned financial executive with more than 25 years of experience across life sciences companies, equity research, and investment banking. As Chief Financial Officer at AtaiBeckley, he will lead the Company’s financial strategy, capital markets activities, and overall financial operations.
Anne Johnson, who has served as Chief Financial Officer since 2024, will transition to the role of Chief Accounting Officer upon the effective date of Mr. Faerm’s appointment. In this position, she will continue to lead accounting and financial operations, working closely with Mr. Faerm to ensure continuity and operational consistency.
“We are delighted to welcome Mike Faerm to AtaiBeckley as our Chief Financial Officer,” said Srinivas Rao, Chief Executive Officer and Co-Founder of Atai Beckley. “Mike brings deep strategic finance experience and a strong understanding of the life sciences sector, which will be important as BPL-003 moves toward Phase 3 and our broader clinical-stage programs continue to advance.”
“We also appreciate Anne’s continued leadership as Chief Accounting Officer. Her operational expertise and familiarity with our financial systems provide important continuity. Together, Mike and Anne create a strong and complementary finance leadership structure for the Company.”
“I’m excited to join AtaiBeckley at this important stage,” said Mr. Faerm. “With BPL-003 advancing toward Phase 3 and a strong clinical-stage pipeline supporting the broader strategy, this is a compelling time to help shape the Company’s financial and capital markets approach. I look forward to leading our financial strategy, partnering with Anne in her role as Chief Accounting Officer, and working closely with the full leadership team to support disciplined execution as the Company moves into late-stage development.”
Mr. Faerm most recently served as Chief Financial Officer at Viracta Therapeutics, Inc. Previously, he was Interim Chief Financial Officer at Harpoon Therapeutics, Inc., which was acquired by Merck, and where he helped lead a $150 million PIPE financing, and Chief Financial Officer of Artiva Biotherapeutics, Inc. Prior to those roles, Mr. Faerm served as the Chief Business Officer of Innoviva, Inc., and earlier, worked in business development and strategic finance roles at Forest Laboratories, Inc. and Regeneron Pharmaceuticals, Inc. Mr. Faerm’s Wall Street experience includes Credit Suisse and Wells Fargo Securities, where he was a senior equity research analyst covering the pharmaceutical sector, and Merrill Lynch, where he was an investment banker executing a wide range of mergers and acquisitions and financing transactions in the biopharma and other healthcare sectors. Mr. Faerm earned an MBA from Harvard Business School, an MS in Civil Engineering from Stanford University, and a BS in Civil Engineering from Columbia University.
About AtaiBeckley Inc.
AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 is in Phase 3 planning, VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
When France and Germany pay for their deficits, fiscal discipline becomes the "moat" of the UK bond market; investors are positioning in advance for a rebound in gilt bonds.
Investors are betting that the new UK Chancellor, Healey, will uphold fiscal discipline and are purchasing gilts in advance. A smooth and steady budget plan is expected to turn the UK from a "risk" in the bond market into a "positive."
Anthropic's $2 Trillion IPO Faces Doubts: Risks of Mismatched Computing Commitments and Revenue
The independent institution New Constructs reported that the Anthropic IPO is absurd, with a valuation of only 150 billion. The main controversy lies in the mismatch between long-term computing power commitments and clients' short-term on-demand procurement models, coupled with macroeconomic headwinds and early investor sell-off pressure, leading to increased market volatility.
Anthropic allocates 5% of shares to set up a fund before IPO, Musk calls for direct distribution to the public
Anthropic announced the establishment of a public welfare fund, initially allocating 5% of its shares. When the company's valuation increases by 50%, another 2% will be added. The aim is to address the impact of AI on employment. Musk suggested directly distributing shares to the public.
AI Stocks Struggle to Rebound: Lacking Three Major Supports, July’s Rally Hard to Replicate
JPMorgan pointed out that due to the absence of ETF bargain-hunting funds, limited room for short covering, and the early termination of the $40 billion buyback by Samsung and SK Hynix, the rebound strength of AI stocks in October may not match that of July. The resurgence of leverage risk could intensify volatility.
Crypto prices
More
